Literature DB >> 1685465

Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.

C U Nwokolo1, J T Smith, A M Sawyerr, R E Pounder.   

Abstract

In a series of 24 hour studies, intragastric acidity and plasma gastrin concentration were measured simultaneously in 46 healthy subjects before, during, and 24 to 48 hours after abrupt withdrawal of a histamine H2 receptor antagonist regimen. For 34 days subjects were given either cimetidine 800 mg at night (n = 8), ranitidine 150 mg twice daily (n = 10), ranitidine 300 mg at night (n = 12), nizatidine 300 mg at night (n = 8), or famotidine 40 mg at night (n = 8). All subjects responded to H2 blockade by a decrease in 24 hour intragastric acidity. Withdrawal of H2 blockade resulted in a significant rise in median nocturnal integrated intragastric acidity in 42 of 46 subjects (+36%; 95% CI +19, +55%) compared with prestudy values, but this rise was not associated with a significant change in the median integrated plasma gastrin concentration (+1%; 95% CI -12, +13%). A statistically significant rise in nocturnal acidity was observed after all regimens, except after dosing with famotidine. After stopping, median daytime integrated acidity and plasma gastrin concentrations in the whole group were raised, but not significantly: values were +15% (95% CI +4, +34%) and +5% (95% CI -2, +12%), respectively. A statistically significant increase in daytime acidity was observed only after dosing with ranitidine. In conclusion, intragastric hyperacidity occurs in most subjects after abrupt withdrawal of a histamine H2 receptor blocker, but this phenomenon is not associated with hypergastrinaemia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685465      PMCID: PMC1379241          DOI: 10.1136/gut.32.12.1455

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  17 in total

1.  Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole.

Authors:  E J Prewett; M Hudson; C U Nwokolo; A M Sawyerr; R E Pounder
Journal:  Gastroenterology       Date:  1991-04       Impact factor: 22.682

2.  Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-hour acidity and gastrin.

Authors:  J T Smith; C Gavey; C U Nwokolo; R E Pounder
Journal:  Aliment Pharmacol Ther       Date:  1990       Impact factor: 8.171

3.  The effects of 15 days of dosing with placebo, sufotidine 600 mg nocte or sufotidine 600 mg twice daily upon 24-hour intragastric acidity and 24-hour plasma gastrin.

Authors:  M J Rogers; J H Holmfield; J N Primrose; D Johnston
Journal:  Aliment Pharmacol Ther       Date:  1990       Impact factor: 8.171

4.  Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine.

Authors:  C U Nwokolo; J T Smith; C Gavey; A Sawyerr; R E Pounder
Journal:  Aliment Pharmacol Ther       Date:  1990       Impact factor: 8.171

Review 5.  Drug-induced changes of plasma gastrin concentration.

Authors:  R Pounder; J Smith
Journal:  Gastroenterol Clin North Am       Date:  1990-03       Impact factor: 3.806

6.  Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist.

Authors:  G M Fullarton; G McLauchlan; A Macdonald; G P Crean; K E McColl
Journal:  Gut       Date:  1989-04       Impact factor: 23.059

7.  Alteration of H2 receptor sensitivity in duodenal ulcer patients after maintenance treatment with an H2 receptor antagonist.

Authors:  D B Jones; C W Howden; D W Burget; C Silletti; R H Hunt
Journal:  Gut       Date:  1988-07       Impact factor: 23.059

8.  Loss of acid suppression during dosing with H2-receptor antagonists.

Authors:  C Wilder-Smith; F Halter; T Ernst; M Gennoni; B Zeyen; L Varga; J J Roehmel; H S Merki
Journal:  Aliment Pharmacol Ther       Date:  1990       Impact factor: 8.171

9.  Maintenance treatment of recurrent peptic ulcer by cimetidine.

Authors:  G Bodemar; A Walan
Journal:  Lancet       Date:  1978-02-25       Impact factor: 79.321

10.  Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects.

Authors:  B Sharma; M Axelson; R P Pounder; P Lundborg; M Ohman; A Santana; M Talbot; C Cederberg
Journal:  Aliment Pharmacol Ther       Date:  1987-02       Impact factor: 8.171

View more
  8 in total

1.  Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors.

Authors:  M J Smit; R Leurs; A E Alewijnse; J Blauw; G P Van Nieuw Amerongen; Y Van De Vrede; E Roovers; H Timmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Feedback control indirect response models.

Authors:  Yaping Zhang; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-07-09       Impact factor: 2.745

3.  Can H2 -receptor upregulation and raised histamine explain an anaphylactoid reaction on cessation of ranitidine in a 19-year-old female? A case report.

Authors:  Susan J Allen; Paul L Chazot; C Jane Dixon
Journal:  Br J Clin Pharmacol       Date:  2018-04-18       Impact factor: 4.335

4.  Up-regulation of H2 receptor and adenylate cyclase in rabbit parietal cells during prolonged treatment with H2-receptor antagonists.

Authors:  K Takeuchi; M Kajimura; M Kodaira; S Lin; H Hanai; E Kaneko
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

5.  Nizatidine, a small molecular compound, enhances killed H5N1 vaccine cell-mediated responses and protects mice from lethal viral challenge.

Authors:  Shuang Wang; Bing Wu; Jia Xue; Ming Wang; Ruiai Chen; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2013-11-19       Impact factor: 3.452

6.  Effects of antisecretory agents on parietal cell structure and H/K-ATPase levels in rabbit gastric mucosa in vivo.

Authors:  D R Scott; M Besancon; G Sachs; H Helander
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

7.  From the H(2) receptor gene to reclassification of the H(2) receptor antagonists.

Authors:  A E Alewijnse
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

8.  The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.

Authors:  Dominic-Luc Webb; Tobias Rudholm-Feldreich; Linda Gillberg; Md Abdul Halim; Elvar Theodorsson; Gareth J Sanger; Colin A Campbell; Malcolm Boyce; Erik Näslund; Per M Hellström
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-24       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.